> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CSL Behring Hereditary Angioedema Therapy OK’d
- URL: https://www.fdaweb.com/csl-behring-hereditary-angioedema-therapy-okd/
- Published: 2017-06-23T12:00:00.000Z
- Updated: 2026-09-14T22:31:15.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5139011

FDA has approved a CSL Behring BLA for Haegarda, the first C1 esterase inhibitor (human) for subcutaneous administration to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients. “The subcutaneous formulation allows patients to administer the product at home to help prevent attacks,” an [FDA release](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm564332.htm?ref=fdaweb.com) says. Haegarda is a human plasma-derived, purified, pasteurized, lyophilized concentrate prepared from large pools of human plasma from U.S. donors. It is indicated for routine prophylaxis to prevent HAE attacks, but is not indicated for treating acute HAE attacks.